Dimensional Fund Advisors
TRML

Dimensional Fund Advisors’s Tourmaline Bio TRML Stock Holding History

Dimensional Fund Advisors’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-69,085
Closed -$3.3M – 3324
2025
Q3 		$3.3M Sell
69,085
-44,806
-39% -$1.24M ﹤0.01% 2644
2025
Q2 		$1.82M Buy
+113,891
New +$1.85M ﹤0.01% 2780
2024
Q2 		– Sell
-13,050
Closed -$299K – 3408
2024
Q1 		$299K Sell
13,050
-7,818
-37% -$276K ﹤0.01% 3135
2023
Q4 		$546K Sell
20,868
-6,409
-23% -$128K ﹤0.01% 3030
2023
Q3 		$766K Buy
27,277
+18,430
+208% +$540K ﹤0.01% 2974
2023
Q2 		$269K Buy
+8,847
New +$226K ﹤0.01% 3186
2022
Q4 		– Sell
-1,788
Closed -$47K – 3517
2022
Q3 		$47K Sell
1,788
-40
-2% -$1.46K ﹤0.01% 3412
2022
Q2 		$82K Buy
+1,828
New +$144K ﹤0.01% 3352

Dimensional Fund Advisors's TRML Position: Q4 2025 in Review

Dimensional Fund Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 69,085 shares — an estimated $3.3M sold.

Dimensional Fund Advisors first reported a position in TRML in Q2 2022 and held it in 8 quarters. The position peaked at $3.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

  • Dimensional Fund Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 69,085 Tourmaline Bio shares in Q4 2025, an estimated $3.3M.
  • Dimensional Fund Advisors first reported a position in Tourmaline Bio in Q2 2022 and held it in 8 quarters.
  • Dimensional Fund Advisors's Tourmaline Bio position peaked at $3.3M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Dimensional Fund Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.